GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ANIP · Mar 31, 2022

ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001023024-22-000008General Corporate
Debt relative to revenue100thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.debt_to_revenue

445.36% · OPTIONAL · VALID

Capex intensity55thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

3.02% · OPTIONAL · VALID

Operating cash generation0thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-29.38% · OPTIONAL · VALID

Revenue growth75thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

18.26% · CORE · VALID

Inventory pressure95thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

128.97% · OPTIONAL · VALID

Operating margin5thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

-29.77% · CORE · VALID

R&D intensity65thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

8.18% · OPTIONAL · VALID

SBC intensity80thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

5.02% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition

What moved in the state?

Balance Sheet Leverage Increased
Previous
132.96%
Current
445.36%
Delta
312.41%
Capex Intensity Increased
Previous
1.18%
Current
3.02%
Delta
1.84%
Cash Generation Decreased
Previous
1.54%
Current
-29.38%
Delta
-30.91%
Growth Increased
Previous
3.67%
Current
18.26%
Delta
14.59%
Inventory Pressure Increased
Previous
37.80%
Current
128.97%
Delta
91.17%
Profitability Decreased
Previous
-18.41%
Current
-29.77%
Delta
-11.36%
R And D Intensity Increased
Previous
5.26%
Current
8.18%
Delta
2.92%
Sbc Intensity Increased
Previous
4.85%
Current
5.02%
Delta
0.17%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · ANIP Fundamental State →Has State · ANI PHARMACEUTICALS INC →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · ANIP CAPEX_INTENSITY_INCREASED →Transitioned To · ANIP CASH_GENERATION_DECREASED →Transitioned To · ANIP GROWTH_INCREASED →Transitioned To · ANIP INVENTORY_PRESSURE_INCREASED →Transitioned To · ANIP PROFITABILITY_DECREASED →Transitioned To · ANIP R_AND_D_INTENSITY_INCREASED →Transitioned To · ANIP SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.